GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Cyclically Adjusted Book per Share

NeuBase Therapeutics (STU:O7P) Cyclically Adjusted Book per Share : €209.83 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

NeuBase Therapeutics's adjusted book value per share for the three months ended in Sep. 2023 was €2.296. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €209.83 for the trailing ten years ended in Sep. 2023.

During the past 12 months, NeuBase Therapeutics's average Cyclically Adjusted Book Growth Rate was -0.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 6.60% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of NeuBase Therapeutics was 9.60% per year. The lowest was -12.30% per year. And the median was 6.05% per year.

As of today (2024-05-24), NeuBase Therapeutics's current stock price is €0.3406. NeuBase Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2023 was €209.83. NeuBase Therapeutics's Cyclically Adjusted PB Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of NeuBase Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.


NeuBase Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for NeuBase Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Cyclically Adjusted Book per Share Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 193.51 209.83

Competitive Comparison of NeuBase Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, NeuBase Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuBase Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Cyclically Adjusted PB Ratio falls into.



NeuBase Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, NeuBase Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2023 was:

Adj_Book= Book Value per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=2.296/129.8595*129.8595
=2.296

Current CPI (Sep. 2023) = 129.8595.

NeuBase Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201312 63.442 98.326 83.788
201403 44.128 99.695 57.480
201406 340.846 100.560 440.158
201409 328.793 100.428 425.150
201412 290.263 99.070 380.474
201503 594.072 99.621 774.393
201506 535.646 100.684 690.862
201509 499.262 100.392 645.811
201512 461.119 99.792 600.053
201603 405.715 100.470 524.393
201606 327.933 101.688 418.783
201609 277.366 101.861 353.606
201612 272.492 101.863 347.386
201703 193.693 102.862 244.530
201706 177.165 103.349 222.610
201709 136.430 104.136 170.131
201712 117.923 104.011 147.229
201803 101.424 105.290 125.092
201806 104.194 106.317 127.267
201809 -0.254 106.507 -0.310
201812 62.618 105.998 76.714
201903 56.348 107.251 68.226
201906 49.682 108.070 59.699
201909 10.664 108.329 12.783
201912 7.407 108.420 8.872
202003 4.227 108.902 5.040
202006 26.643 108.767 31.810
202009 22.950 109.815 27.139
202012 20.227 109.897 23.901
202103 17.349 111.754 20.160
202106 30.583 114.631 34.646
202109 28.092 115.734 31.521
202112 25.460 117.630 28.107
202203 21.484 121.301 23.000
202206 17.778 125.017 18.467
202209 14.193 125.227 14.718
202212 10.377 125.222 10.761
202303 7.982 127.348 8.139
202306 5.527 128.729 5.576
202309 2.296 129.860 2.296

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


NeuBase Therapeutics  (STU:O7P) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NeuBase Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.3406/209.83
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of NeuBase Therapeutics was 0.01. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


NeuBase Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (STU:O7P) Business Description

Industry
Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines